Merck leads, Amgen in second, Pfizer trails in 2026’s stock race among large U.S. drugmakers

So far in 2026, investors have been rewarding Merck more than its large-cap drugmaking peers, according to a market rundown comparing Merck, Pfizer and Amgen. The comparison is based on stock performance year to date, with Merck positioned as the front-runner among the three.

In the ranking presented by the article, Merck’s shares lead the group, described as up about 44% for the year at the time of publication. Amgen is placed in second position, while Pfizer is described as trailing, described as a “distant third” versus the other two names.

The post frames the relative differences as a simple question of which stock has “dominated” among major U.S. drugmakers in 2026 so far. It does not attribute the move to any single factor in the provided text, nor does it break down drivers such as revenue trends, pipeline updates, or margin changes for each company.

For Pfizer, the limited information in the article means readers do not get a granular explanation for why the stock is lagging the peer comparison. Without additional detail from the post, it is not possible to determine whether the underperformance reflects investor expectations for near-term earnings, reactions to specific product milestones, or broader sentiment toward large pharmaceutical companies.

For context, Merck and Amgen have both benefited in recent years from blockbuster-era therapies and a pipeline focus that investors monitor closely. Pfizer, meanwhile, has often been viewed through the lens of its larger-scale biopharma portfolio and the progress of later-stage candidates. Even so, the article’s comparative framing does not provide company-by-company proof points for the year-to-date divergence.

The most important limitation of the market snapshot is that it is comparative and timing-specific. A year-to-date leaderboard can shift quickly as markets react to trial readouts, regulatory decisions, guidance updates, and competitor news. The post also does not clarify whether the performance figures are based on price return alone, which can matter when dividends are included.

Investors watching this peer set next will likely look for catalysts that typically move large drugmakers’ stocks: earnings guidance changes, material pipeline trial outcomes, and any major regulatory or commercialization updates tied to flagship products. For Pfizer specifically, what would help clarify the “distant third” placement would be any disclosed earnings or pipeline narrative that management is emphasizing going into later 2026 quarters.

What is not disclosed in the article is just as notable as what is. In the provided information, there are no details on magnitude beyond the general ranking, no breakdown by segment, and no identification of the particular headlines that propelled Merck or weighed on Pfizer during 2026 so far.